TY - JOUR
T1 - 90Yttrium-ibritumomab tiuxetan
T2 - A novel treatment for non-Hodgkin's lymphoma
AU - Blum, Kristie A.
AU - Bartlett, Nancy L.
PY - 2004/8
Y1 - 2004/8
N2 - Indolent non-Hodgkin's lymphomas (NHLs) comprise 35-40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttrium-ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67-80%, with a median remission duration of ∼ 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium- ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.
AB - Indolent non-Hodgkin's lymphomas (NHLs) comprise 35-40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttrium-ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67-80%, with a median remission duration of ∼ 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium- ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.
KW - Monoclonal antibody
KW - Non-Hodgkin's lymphoma
KW - Radioimmunoconjugate
KW - Radioimmunotherapy
KW - Yttrium-ibritumomab tiuxetan
UR - http://www.scopus.com/inward/record.url?scp=3442894823&partnerID=8YFLogxK
U2 - 10.1517/14712598.4.8.1323
DO - 10.1517/14712598.4.8.1323
M3 - Review article
C2 - 15268665
AN - SCOPUS:3442894823
SN - 1471-2598
VL - 4
SP - 1323
EP - 1331
JO - Expert opinion on biological therapy
JF - Expert opinion on biological therapy
IS - 8
ER -